Clinical Trial Update: A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial evaluating trilaciclib to prevent chemotherapy-related myelosuppression in patients with Ewing's sarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Myelosuppression
• Ewing Sarcoma

Drugs mentioned

• Cosela (trilaciclib)

Snippet

Sponsor: Fudan University | Conditions: Ewing Sarcoma, Myelosuppression | Phase 2 | Status: RECRUITING